• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes

by | Feb 27, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Deep Responses in Smoldering Multiple Myeloma Linked to Improved Outcomes

by | Feb 26, 2025 | Myeloma News

Source: Pharmacy Times articles Risk stratification remains a challenge when selecting patients for treatment of smoldering multiple myeloma. Read More

Urine-free response criteria predict progression-free survival in multiple myeloma: a post hoc analysis of BMT CTN 0702

by | Feb 25, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma

by | Feb 21, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

High WEE1 expression is independently linked to poor survival in multiple myeloma

by | Feb 21, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

FDA Grants OPN-6602 Orphan Drug Destination for Treatment of Patients With Relapsed, Refractory Multiple Myeloma

by | Feb 14, 2025 | Myeloma News

Source: Pharmacy Times articles OPN-6602 is an oral EP300/CBP bromodomain inhibitor that yielded 100% tumor regression as a combination therapy in mouse models. Read More
« Older Entries
Next Entries »

Recent Content

  • Efficacy and Safety of Quadruplet Therapy in Newly Diagnosed Transplant-Eligible Multiple Myeloma: A Systematic Review and Meta-Analysis
  • Nivolumab May Restore T-Cell Fitness Following CAR T-Cell Therapy in Patients With Multiple Myeloma
  • Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study
  • Non-relapse mortality with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma
  • Prognostic and clinicopathological value of the controlling nutritional status score in patients with multiple myeloma: a meta-analysis
  • What Role Does MRD Play in Multiple Myeloma Treatment Decision Making?
  • Depression, anxiety prevalent among adults with lymphoma, multiple myeloma
  • Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysis
  • Brain-to-vein and vein-to-vein times and outcomes in CAR T-cell therapy in myeloma
  • Quadruplet Regimen Preferable to Triplets in Multiple Myeloma
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT